CURIS, INC. Research and Development Expense
CURIS, INC. (CRIS) reported Research and Development Expense of $18.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2018-03-08
- CURIS, INC. research and development expense for the quarter ending 2015-06-30 was $2.00M, a 39.92% decline year-over-year.
- CURIS, INC. research and development expense for the quarter ending 2014-12-31 was $3.48M, a 17.50% increase year-over-year.
- CURIS, INC. research and development expense for the quarter ending 2014-09-30 was $3.71M, a 11.16% decline year-over-year.
- CURIS, INC. research and development expense for the quarter ending 2014-06-30 was $3.33M, a 5.13% increase year-over-year.
- CURIS, INC. research and development expense for fiscal 2016 was $18.00M.
- CURIS, INC. research and development expense for fiscal 2014 was $13.66M, a 5.67% increase from fiscal 2013.
- CURIS, INC. research and development expense for fiscal 2013 was $12.93M, a 16.56% decline from fiscal 2012.
- CURIS, INC. research and development expense for fiscal 2012 was $15.49M, a 13.14% increase from fiscal 2011.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2016-12-31 | $18.00M 10-K · filed 2018-03-08 | |||
| 2015-06-30 | $2.00M 10-Q · filed 2015-08-06 | $2.00M 10-Q · filed 2015-08-06 | ||
| 2014-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $7.18M derived: sum of 2 quarters · filed 2015-02-24 | $10.51M derived: sum of 3 quarters · filed 2015-02-24 | $13.66M 10-K · filed 2015-02-24 |
| 2014-09-30 | $3.71M 10-Q · filed 2014-11-10 | $7.03M derived: sum of 2 quarters · filed 2014-11-10 | $10.18M 10-Q · filed 2014-11-10 | $13.14M derived: sum of 4 quarters · filed 2015-02-24 |
| 2014-06-30 | $3.33M 10-Q · filed 2014-08-07 | $6.47M 10-Q · filed 2014-08-07 | $9.44M derived: sum of 3 quarters · filed 2015-02-24 | $13.61M derived: sum of 4 quarters · filed 2015-02-24 |
| 2014-03-31 | $3.15M 10-Q · filed 2014-05-09 | $6.11M derived: sum of 2 quarters · filed 2015-02-24 | $10.28M derived: sum of 3 quarters · filed 2015-02-24 | $13.44M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $7.13M derived: sum of 2 quarters · filed 2015-02-24 | $10.30M derived: sum of 3 quarters · filed 2015-02-24 | $12.93M 10-K · filed 2015-02-24 |
| 2013-09-30 | $4.17M 10-Q · filed 2014-11-10 | $7.34M derived: sum of 2 quarters · filed 2014-11-10 | $9.97M 10-Q · filed 2014-11-10 | $12.67M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $3.17M 10-Q · filed 2014-08-07 | $5.80M 10-Q · filed 2014-08-07 | $8.50M derived: sum of 3 quarters · filed 2015-02-24 | $11.54M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $2.63M 10-Q · filed 2014-05-09 | $5.34M derived: sum of 2 quarters · filed 2015-02-24 | $8.38M derived: sum of 3 quarters · filed 2015-02-24 | $12.88M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $5.75M derived: sum of 2 quarters · filed 2015-02-24 | $10.25M derived: sum of 3 quarters · filed 2015-02-24 | $15.49M 10-K · filed 2015-02-24 |
| 2012-09-30 | $3.04M 10-Q · filed 2013-11-12 | $7.54M derived: sum of 2 quarters · filed 2013-11-12 | $12.78M 10-Q · filed 2013-11-12 | $17.23M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-06-30 | $4.50M 10-Q · filed 2013-08-08 | $9.74M 10-Q · filed 2013-08-08 | $14.19M derived: sum of 3 quarters · filed 2014-03-13 | $17.23M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-03-31 | $5.24M 10-Q · filed 2013-05-09 | $9.69M derived: sum of 2 quarters · filed 2014-03-13 | $12.73M derived: sum of 3 quarters · filed 2014-03-13 | $15.88M derived: sum of 4 quarters · filed 2014-03-13 |
| 2011-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $7.49M derived: sum of 2 quarters · filed 2014-03-13 | $10.63M derived: sum of 3 quarters · filed 2014-03-13 | $13.69M 10-K · filed 2014-03-13 |
| 2011-09-30 | $3.04M 10-Q · filed 2012-11-06 | $6.19M derived: sum of 2 quarters · filed 2012-11-06 | $9.24M 10-Q · filed 2012-11-06 | $12.90M derived: sum of 4 quarters · filed 2013-03-13 |
| 2011-06-30 | $3.14M 10-Q · filed 2012-08-09 | $6.20M 10-Q · filed 2012-08-09 | $9.85M derived: sum of 3 quarters · filed 2013-03-13 | $12.86M derived: sum of 4 quarters · filed 2013-03-13 |
| 2011-03-31 | $3.06M 10-Q · filed 2012-05-10 | $6.71M derived: sum of 2 quarters · filed 2013-03-13 | $9.72M derived: sum of 3 quarters · filed 2013-03-13 | $11.96M derived: sum of 4 quarters · filed 2013-03-13 |
| 2010-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-13 | $6.66M derived: sum of 2 quarters · filed 2013-03-13 | $8.91M derived: sum of 3 quarters · filed 2013-03-13 | $11.37M 10-K · filed 2013-03-13 |
| 2010-09-30 | $3.01M 10-Q · filed 2011-10-31 | $5.25M derived: sum of 2 quarters · filed 2011-10-31 | $7.72M 10-Q · filed 2011-10-31 | |
| 2010-06-30 | $2.24M 10-Q · filed 2011-08-04 | $4.71M 10-Q · filed 2011-08-04 | ||
| 2009-12-31 | $9.93M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |